A compound that mimics testosterone just improved heart performance in elderly mice. The bigger surprise is that the benefit wasn't equal for males and females, and a single inflammation marker seemed to track with how well male hearts worked. Before anyone starts shopping for research chemicals, here is what the study found and what it doesn't show.
What the researchers actually did
A Dalhousie University team (Heinze, Sapp, Young and Howlett), publishing in Geroscience, studied 23-month-old male and female mice, which are elderly in mouse terms. They gave the animals RAD140, a selective androgen receptor modulator (SARM), at 5 mg/kg/day for 6 weeks.
The team then used echocardiography to measure left ventricular structure and function. They also ran a multiplex assay on serum cytokines (inflammatory signaling molecules) and tested gene expression in the heart.
The rationale is that low testosterone in humans is linked to weaker cardiac function and higher circulating inflammatory markers, and those two problems appear mechanistically connected. SARMs are designed to activate androgen receptors (ARs) and mimic some of testosterone's effects. The open question was whether they change the aging heart, and whether inflammation tracks with any change.
The headline numbers
Compared with untreated controls, RAD140-treated mice of both sexes showed:
- Ejection fraction up 10.4%
- Stroke volume up 9.6 µL
- Cardiac output up 4.5 mL/min
Those are the pump-performance measures, and they moved in the right direction in males and females alike.
Where males pulled ahead
The finer measures of how the heart contracts and relaxes told a different story. RAD140-treated males had better:
- Myocardial strain (-5.8%), a measure of how effectively heart muscle deforms with each beat
- Isovolumic relaxation time (-4.7 ms), a measure of how quickly the ventricle relaxes between beats
In females, these effects were lesser or even opposite. The authors conclude that RAD140 may enhance cardiac function in older male mice, but less so in older female mice.
The interleukin-6 twist
Higher interleukin-6 (IL-6), a well-known inflammatory cytokine, correlated with worse global circumferential strain in males, but not in females. The authors link greater circumferential strain in treated males to lower IL-6 levels, and they read this as support for the androgen receptor acting as a bridge between cardiac function and inflammation.
This is a correlation within an animal study. The data don't show that RAD140 improved the heart by lowering IL-6, only that the two moved together in males.
What didn't change
- No structural differences. Heart structure was the same between groups, so the gains were functional rather than a remodeled heart.
- No gene expression shifts. The qPCR panel of genes tied to cardiac function and structure showed no differences.
- Lower AR mRNA. Androgen receptor mRNA was reduced with RAD140 in both sexes, a sign the receptor system adapts to the drug. The paper doesn't establish what that means functionally.
Practical takeaways: dose, timing, who it's for
This is where hype tends to outrun the evidence, so here is the plain version.
Dose: The only dose tested was 5 mg/kg/day in mice. This study provides no human dose, and mouse doses don't convert cleanly into safe or effective human ones.
Timing: The protocol was 6 weeks of daily treatment in very old mice. There is no data here on optimal timing, cycling, or long-term effects.
Who it's for: Based on this paper, nobody yet. It is a preclinical result. If anything, it suggests that sex could matter a great deal in any future cardiac-focused SARM research, since benefits looked clearer in males and females showed weaker or opposite responses on some measures.
Safety context: RAD140 is an investigational compound, not an approved therapy, and this study did not assess safety in humans. SARMs sold online are unregulated, and the paper offers no reason to self-experiment. Anyone with heart concerns or low testosterone should talk to a physician about approved, monitored options.
Why it still matters for longevity
Cardiac decline is a core feature of aging, and inflammation is a leading suspect in why. This study fits a broader geroscience idea: hormone signaling, inflammation and organ function are tangled together, and sex-specific biology can change how an intervention works. A compound that improves pump function in 23-month-old mice without needing structural remodeling is worth following, as long as it is understood for what it is.
Bottom line
- Evidence level: Animal study in older mice, 6 weeks, one dose.
- Solid finding: Ejection fraction, stroke volume and cardiac output rose in both sexes.
- Male-specific edge: Strain and relaxation improved more in males, and IL-6 correlated with strain only in males.
- Limits: No structural or gene expression changes, no causal proof for the IL-6 link, and no human data.
The finding is promising for understanding androgen signaling and cardiac aging, but it is a starting point for human research rather than a protocol.